Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study established an experimental model to visualize calcium ion distribution after skin barrier damage in canine epidermis, observing that calcium gradients changed differently depending on the type of damage and time elapsed.

This article reviews alopecia areata treatments, noting varied outcomes, and reports no new clinical results.

This study found that intralesional triamcinolone acetonide injections using a needleless injector led to rapid hair regrowth in patients with limited alopecia areata, while lasting growth was rare in alopecia totalis.

This study found that both intralesional triamcinolone acetonide and triamcinolone hexacetonide promote continuous hair growth in alopecia areata, with effects lasting at least 9 months after a single injection.

Microneedling combined with triamcinolone can safely stimulate faster hair regrowth in people with Alopecia Areata.

This study found that 2.5 mg/mL triamcinolone acetonide injections were as effective as higher doses for treating limited, patchy alopecia areata, while minimizing side effects like skin atrophy.

The authors concluded that intralesional triamcinolone acetonide may benefit patients with patch-type alopecia areata, but the evidence is limited due to small, bias-prone studies with variations in treatment protocols.

This study suggests that intralesional triamcinolone acetonide at a concentration of 5 mg/mL may offer the best balance of effectiveness and safety for treating focal alopecia areata.

This study found that intralesional triamcinolone was more effective than topical betamethasone for hair regrowth in patients with localized alopecia areata.

This study found that intralesional steroid treatment led to significantly more hair regrowth in alopecia areata patients than narrow band ultraviolet B therapy, while their combination did not enhance effectiveness.

This article reports a case of linear lichen planus developing along the lines of Blaschko during intramuscular triamcinolone acetonide therapy for alopecia areata multiplex.

This study found that intramuscular triamcinolone acetonide may be an effective and safe treatment option for managing refractory alopecia areata, showing a 63% response rate in patients and hair regrowth negatively correlated with initial scalp involvement.

This study found that intralesional triamcinolone acetonide injections effectively increased hair density in African American women with traction alopecia, showing promise as a safe treatment option.

This article reviews triamcinolone acetonide as an intramuscular long-acting steroid therapy for dermatologic disorders but reports no new clinical results.

In this study, PRP injections showed comparable effectiveness to triamcinolone for alopecia areata, with a significant decrease in SALT score at one interval, and 12.5% of patients in the PRP group experienced excellent hair regrowth compared to none in the triamcinolone group.

This study reported that intralesional triamcinolone acetonide was more effective than intralesional PRP for treating scalp alopecia areata, with minimal recurrence and side effects like atrophy and hypopigmentation.

This study reported that black hairy tongue was rapidly resolved with topical triamcinolone acetonide, suggesting further trials for its treatment are warranted.

This study found that intralesional injections of triamcinolone acetonide at 5 mg/mL are as effective and safe as 10 mg/mL for treating patchy alopecia areata on the scalp, with similar hair regrowth rates, side effects, and recurrence observed between the two dosages.

This case report highlights that intradermal testing may be more effective than patch testing for diagnosing delayed hypersensitivity reactions to intralesional corticosteroids like triamcinolone acetonide.

This study found that intralesional triamcinolone acetonide was more effective than saline for hair regrowth in scalp alopecia areata, with 10 mg/mL showing the best response but more side effects.

In this study, researchers found that triamcinolone acetonide provided earlier visual improvement in alopecia areata treatment, but by 12 weeks, both triamcinolone acetonide and betamethasone 1.75 mg/ml showed similar effectiveness compared to lower-dose betamethasone and placebo.

In this study, 70 patients with alopecia areata who received intralesional triamcinolone showed a significant reduction in black dots, yellow dots, broken hair, and tapering hair, while achieving a 60% success rate in hair regrowth.

This case series reported incidents of iatrogenic Cushing's Syndrome linked to high doses of intralesional corticosteroid injections and mesotherapy regimens, highlighting the need for cautious prescription practices and further research on mesotherapy safety.

This study found that combining 308-excimer phototherapy with intramuscular triamcinolone acetonide was effective and well tolerated for treating resistant alopecia totalis, showing a 90% overall response rate in the ten patients studied, with the best results observed in younger patients.

This study found that bulge keratinocytes in mice develop resistance to glucocorticoid treatment more slowly than interfollicular keratinocytes and do not significantly aid in repairing glucocorticoid-induced skin atrophy within five days.

This study reported that while Intralesional Triamcinolone Acetonide injections effectively improved mouth opening in patients with Oral Submucous Fibrosis, it also led to symptoms of Cushing's Syndrome, highlighting the need for careful monitoring of adverse effects.

This study found that intralesional triamcinolone acetonide at both 5 mg/mL and 10 mg/mL concentrations had similar effectiveness and safety for treating patchy alopecia areata on the scalp, with no significant difference in response rates or side effects between the two dosage groups.

This study suggests that peri-incisional triamcinolone acetonide may subtly benefit wound edge apposition in low-tension scalp regions during hair restoration surgery, but shows no statistically significant overall effect.

In this case report, a 35-year-old man developed avascular necrosis after receiving intradermal corticosteroid injections for alopecia areata, marking the first documented instance of this side effect from such treatment.

This study found that platelet-rich plasma showed similar efficacy to intralesional triamcinolone acetonide for treating mild patch-type alopecia areata, offering a potential alternative with fewer steroid-related side effects.